Skip to main content

West Pharmaceutical Services Value Stock - Dividend - Research Selection

West pharmaceutical services

ISIN: US9553061055 , WKN: 864330

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

2026-06-17
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

LivaNova Reports Improved OSA Outcomes With PolySync Programming

2026-06-17
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

Reasons to Retain Baxter International Stock in Your Portfolio for Now

2026-06-16
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

2026-06-16
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

DXCM Receives FDA Clearance for Stelo OTC CGM System for Children

2026-06-16
DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

Here's Why You Should Retain BDX Stock in Your Portfolio Now

2026-06-16
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

How Investors May Respond To West Pharmaceutical Services (WST) Upgraded 2026 Outlook And Biologics Momentum

2026-06-16
West Pharmaceutical Services recently reported strong first-quarter 2026 results, highlighting robust growth in biologics-related high-value components and self-injection delivery devices, and raised its full-year 2026 revenue and adjusted EPS guidance. The company emphasized its role as a critical part of injectable-drug infrastructure rather than a conventional packaging supplier, underlining how its specialized high-value products support complex biologic therapies. Next, we’ll examine...

QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use

2026-06-15
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.

GEHC Expands Carilion Tie to Enhance Patient Care Across Virginia

2026-06-15
GE HealthCare expands its Carilion Clinic collaboration with AAMP and Encompass to improve equipment management and operational efficiency across Virginia.

Is West Pharmaceutical Stock Outperforming the S&P 500?

2026-06-15
West Pharmaceutical continues to outpace broader market gains on strong earnings momentum and supportive analyst sentiment.